Erasca (NASDAQ:ERAS) Announces Earnings Results

Posted by Brenda Bartman on May 11th, 2026

Erasca (NASDAQ:ERAS – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.41), FiscalAI reports.

Erasca Price Performance

Shares of ERAS traded up $0.32 during mid-day trading on Monday, reaching $10.44. The company had a trading volume of 3,784,731 shares, compared to its average volume of 7,225,225. Erasca has a twelve month low of $1.06 and a twelve month high of $24.28. The company’s 50-day moving average is $15.68 and its 200-day moving average is $9.29. The company has a market capitalization of $3.25 billion, a P/E ratio of -23.73 and a beta of 0.68.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ERAS. Piper Sandler upped their price objective on shares of Erasca from $11.00 to $18.00 and gave the company an “overweight” rating in a research report on Friday, March 13th. Mizuho boosted their price target on Erasca from $16.00 to $19.00 and gave the company an “outperform” rating in a research note on Friday, March 13th. Citigroup reaffirmed a “buy” rating on shares of Erasca in a report on Friday, March 13th. JPMorgan Chase & Co. raised their price objective on Erasca from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Erasca in a research report on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.88.

View Our Latest Analysis on ERAS

Insider Buying and Selling at Erasca

In other Erasca news, insider Ebun Garner sold 80,000 shares of Erasca stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $16.40, for a total transaction of $1,312,000.00. Following the completion of the transaction, the insider directly owned 25,076 shares of the company’s stock, valued at approximately $411,246.40. This trade represents a 76.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Morris sold 20,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $15.04, for a total transaction of $300,800.00. The SEC filing for this sale provides additional information. 14.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Erasca

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its stake in Erasca by 58.0% in the second quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock worth $27,000 after purchasing an additional 7,923 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Erasca in the second quarter valued at $29,000. Russell Investments Group Ltd. bought a new position in shares of Erasca in the third quarter valued at about $31,000. Stifel Financial Corp bought a new position in shares of Erasca in the fourth quarter valued at about $38,000. Finally, EntryPoint Capital LLC acquired a new position in Erasca during the 4th quarter worth about $38,000. 67.78% of the stock is owned by institutional investors and hedge funds.

Erasca Company Profile

(Get Free Report)

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.